Alife Health’s AI Embryo Selection Platform Secures CE Mark for IVF Use in Europe

Alife Health has earned CE Mark approval under the European Medical Device Regulation for Embryo Predict, its AI-driven embryo selection software. Designed to assist embryologists during in vitro fertilisation (IVF), the tool integrates seamlessly with existing lab systems to capture embryo images, generate AI-based viability scores, and rank embryos by their likelihood of leading to a successful pregnancy. By standardising embryo assessment, Embryo Predict minimises the variability common in traditional evaluation methods and enhances consistency through data-driven insights. The platform uses deep learning to identify subtle developmental patterns linked to implantation success. Following certification, Alife plans to roll out the tool across select EU fertility clinics. The company already operates in the US, supporting IVF networks through its Clinical Decision Support platform to improve fertility outcomes globally.

28-10-2025